# O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

> **NCT00961220** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7

## Interventions

- **DRUG:** Carmustine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** O6-Benzylguanine

## Key facts

- **NCT ID:** NCT00961220
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-01
- **Primary completion:** 2012-04-08
- **Final completion:** 2014-04-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961220, "O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00961220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*